These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 17724438)
1. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Amarasinghe K; Dalley C; Dokal I; Laurie A; Gupta V; Marsh J Bone Marrow Transplant; 2007 Nov; 40(9):913-4. PubMed ID: 17724438 [No Abstract] [Full Text] [Related]
2. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Dietz AC; Orchard PJ; Baker KS; Giller RH; Savage SA; Alter BP; Tolar J Bone Marrow Transplant; 2011 Jan; 46(1):98-104. PubMed ID: 20383216 [TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. Rzepecki P; Sarosiek T; Szczylik C Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840 [TBL] [Abstract][Full Text] [Related]
4. Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita. Brown M; Myers D; Shreve N; Rahmetullah R; Radhi M Bone Marrow Transplant; 2016 May; 51(5):744-6. PubMed ID: 26808569 [No Abstract] [Full Text] [Related]
5. The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience. Chakrabarti S; Mackinnon S Transplant Proc; 2003 Feb; 35(1):172-3. PubMed ID: 12591353 [No Abstract] [Full Text] [Related]
6. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Kharfan-Dabaja MA; Otrock ZK; Bacigalupo A; Mahfouz RA; Geara F; Bazarbachi A Bone Marrow Transplant; 2012 Sep; 47(9):1254-5. PubMed ID: 22246089 [No Abstract] [Full Text] [Related]
7. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Kröger N; Shaw B; Iacobelli S; Zabelina T; Peggs K; Shimoni A; Nagler A; Binder T; Eiermann T; Madrigal A; Schwerdtfeger R; Kiehl M; Sayer HG; Beyer J; Bornhäuser M; Ayuk F; Zander AR; Marks DI; Br J Haematol; 2005 Jun; 129(5):631-43. PubMed ID: 15916686 [TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S; Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309 [TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271 [TBL] [Abstract][Full Text] [Related]
10. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Bitan M; Or R; Shapira MY; Aker M; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060 [TBL] [Abstract][Full Text] [Related]
11. Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen. Algeri M; Comoli P; Strocchio L; Perotti C; Corbella F; Del Fante C; Baio A; Giorgiani G; Gurrado A; Accornero E; Cugno C; Pession A; Zecca M J Pediatr Hematol Oncol; 2015 May; 37(4):322-6. PubMed ID: 25374286 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. van Besien K; Artz A; Smith S; Cao D; Rich S; Godley L; Jones D; Del Cerro P; Bennett D; Casey B; Odenike O; Thirman M; Daugherty C; Wickrema A; Zimmerman T; Larson RA; Stock W J Clin Oncol; 2005 Aug; 23(24):5728-38. PubMed ID: 16009946 [TBL] [Abstract][Full Text] [Related]
15. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bolaños-Meade J; Luznik L; Muth M; Matsui WH; Huff CA; Smith BD; Levy MY; Kasamon YL; Swinnen LJ; Powell JD; Brodsky RA; Ambinder RF; Jones RJ; Fuchs EJ Bone Marrow Transplant; 2009 Mar; 43(6):477-80. PubMed ID: 18978825 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Hansen MD; Filipovich AH; Davies SM; Mehta P; Bleesing J; Jodele S; Hayashi R; Barnes Y; Shenoy S Bone Marrow Transplant; 2008 Feb; 41(4):349-53. PubMed ID: 18026148 [TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bhatla D; Davies SM; Shenoy S; Harris RE; Crockett M; Shoultz L; Smolarek T; Bleesing J; Hansen M; Jodele S; Jordan M; Filipovich AH; Mehta PA Bone Marrow Transplant; 2008 Aug; 42(3):159-65. PubMed ID: 18500373 [TBL] [Abstract][Full Text] [Related]
18. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114 [TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. Ostronoff F; Ostronoff M; Calixto R; Florêncio R; Domingues MC; Souto Maior AP; Sucupira A; Tagliari C Biol Blood Marrow Transplant; 2007 Mar; 13(3):366-8. PubMed ID: 17317590 [No Abstract] [Full Text] [Related]
20. Chimerism does not predict for outcome after alemtuzumab based conditioning. Michaelis L; Lin S; Joseph L; Artz AS; Kline J; Pollyea D; Stock W; Rich E; Collins-Jones D; Casey B; Del Cerro P; van Besien K Bone Marrow Transplant; 2007 Jul; 40(2):181. PubMed ID: 17502895 [No Abstract] [Full Text] [Related] [Next] [New Search]